These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 20010526)
1. Correlation between histological type and immunohistochemical profile of prostate cancer and gleason scale gradation. Iemelynova AA; Grygorenko VM; Cheremuha SV; Romanenko AM Exp Oncol; 2009 Dec; 31(4):246-9. PubMed ID: 20010526 [TBL] [Abstract][Full Text] [Related]
2. Ki-67 antigen and P53 protein expression in benign and malignant prostatic lesions. Immunohistochemical quantitative study. Sasor A; Wagrowska-Danilewicz M; Danilewicz M Pol J Pathol; 2000; 51(1):31-6. PubMed ID: 10833901 [TBL] [Abstract][Full Text] [Related]
3. Increased p53 immunoreactivity in proliferative inflammatory atrophy of prostate is related to focal acute inflammation. Wang W; Bergh A; Damber JE APMIS; 2009 Mar; 117(3):185-95. PubMed ID: 19245591 [TBL] [Abstract][Full Text] [Related]
4. Apoptosis in prostate cancer: bax correlation with stage. Amirghofran Z; Monabati A; Gholijani N Int J Urol; 2005 Apr; 12(4):340-5. PubMed ID: 15948719 [TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical study of cell proliferation, Bcl-2, p53, and caspase-3 expression on preneoplastic changes induced by cadmium and zinc chloride in the ventral rat prostate. Arriazu R; Pozuelo JM; Henriques-Gil N; Perucho T; Martín R; Rodríguez R; Santamaría L J Histochem Cytochem; 2006 Sep; 54(9):981-90. PubMed ID: 16585387 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate. Tamboli P; Amin MB; Xu HJ; Linden MD Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470 [TBL] [Abstract][Full Text] [Related]
7. Amphiregulin expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 93 cases. Bostwick DG; Qian J; Maihle NJ Prostate; 2004 Feb; 58(2):164-8. PubMed ID: 14716741 [TBL] [Abstract][Full Text] [Related]
8. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x. Pollack A; Cowen D; Troncoso P; Zagars GK; von Eschenbach AC; Meistrich ML; McDonnell T Cancer; 2003 Apr; 97(7):1630-8. PubMed ID: 12655519 [TBL] [Abstract][Full Text] [Related]
9. Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate. Uetsuki H; Tsunemori H; Taoka R; Haba R; Ishikawa M; Kakehi Y J Urol; 2005 Aug; 174(2):514-8. PubMed ID: 16006883 [TBL] [Abstract][Full Text] [Related]
10. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. Cheng L; Sebo TJ; Cheville JC; Pisansky TM; Slezak J; Bergstralh EJ; Pacelli A; Neumann RM; Zincke H; Bostwick DG Cancer; 1999 Mar; 85(6):1293-9. PubMed ID: 10189134 [TBL] [Abstract][Full Text] [Related]
11. Morphological transition of proliferative inflammatory atrophy to high-grade intraepithelial neoplasia and cancer in human prostate. Wang W; Bergh A; Damber JE Prostate; 2009 Sep; 69(13):1378-86. PubMed ID: 19507201 [TBL] [Abstract][Full Text] [Related]
12. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Baretton GB; Klenk U; Diebold J; Schmeller N; Löhrs U Br J Cancer; 1999 May; 80(3-4):546-55. PubMed ID: 10408865 [TBL] [Abstract][Full Text] [Related]
13. The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome. Tsamandas AC; Kardamakis D; Tsiamalos P; Liava A; Tzelepi V; Vassiliou V; Petsas T; Vagenas K; Zolota V; Scopa CD Anticancer Res; 2009 Feb; 29(2):703-9. PubMed ID: 19331225 [TBL] [Abstract][Full Text] [Related]
14. The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions. Dimitrakakis C; Kymionis G; Diakomanolis E; Papaspyrou I; Rodolakis A; Arzimanoglou I; Leandros E; Michalas S Gynecol Oncol; 2000 Apr; 77(1):129-36. PubMed ID: 10739702 [TBL] [Abstract][Full Text] [Related]
15. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer. Das S; Roth CP; Wasson LM; Vishwanatha JK Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178 [TBL] [Abstract][Full Text] [Related]
16. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer. Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751 [TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of Bcl-2 in clinically localized prostate cancer. Bubendorf L; Sauter G; Moch H; Jordan P; Blöchlinger A; Gasser TC; Mihatsch MJ Am J Pathol; 1996 May; 148(5):1557-65. PubMed ID: 8623924 [TBL] [Abstract][Full Text] [Related]
19. The utility of Ki-67 expression in the differential diagnosis of prostatic intraepithelial neoplasia and ductal adenocarcinoma. Rioux-Leclercq N; Leray E; Patard JJ; Lobel B; Guillé F; Jouan F; Bellaud P; Epstein JI Hum Pathol; 2005 May; 36(5):531-5. PubMed ID: 15948120 [TBL] [Abstract][Full Text] [Related]
20. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis. Erdamar S; Yang G; Harper JW; Lu X; Kattan MW; Thompson TC; Wheeler TM Mod Pathol; 1999 Aug; 12(8):751-5. PubMed ID: 10463475 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]